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Vitamin K epoxide reductase and its 
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structures and functions
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Vitamin K epoxide reductase (VKOR) is an essential enzyme for vitamin K-dependent carboxylation, 
while the physiological function of its paralogous enzyme VKOR-like (VKORL) is yet unknown. Although 
these two enzymes share approximately 50% protein sequence homology, the membrane topology 
of VKOR is still in debate. Here, we explored the differences in the membrane topology and disulfide-
linked oligomerization of these two enzymes. Results from mutating the critical amino acid residues in 
the disputed transmembrane (TM) regions revealed that the second TM domain in the proposed 4-TM 
model of VKOR does not function as an authentic TM helix; supporting VKOR is a 3-TM protein, which 
is different from VKORL. Additionally, altering the loop sequence between the two conserved cysteine 
residues of VKORL affects its activity, supporting the notion that the conserved loop cysteines of VKORL 
are involved in its active site regeneration. However, a similar mutation in VKOR does not affect its 
enzymatic activity. Finally, our results show that although both VKOR and VKORL form disulfide-linked 
oligomers, the cysteine residues involved in the oligomerization appear to be different. Overall, the 
structural and functional differences between VKOR and VKORL shown here indicate that VKORL might 
have a different physiological function other than recycling vitamin K.
Vitamin K is a family of 2-methyl-1,4-naphthoquinone derivatives that includes the naturally occurring menaqui-
nones and phylloquinone. In mammals, the primary function of vitamin K is to act as a cofactor for the enzyme 
gamma-glutamyl carboxylase (GGCX)1. About 70% of vitamin K absorbed from the diet is lost to excretion. 
Therefore, the body’s stores of vitamin K are recycled in a process known as the vitamin K cycle1,2. In the vitamin 
K cycle, an endoplasmic reticulum (ER) membrane protein called vitamin K epoxide reductase (VKOR) reduces 
vitamin K 2,3-epoxide (KO) to vitamin K (K); this vitamin K is then further reduced to vitamin K hydroquinone 
(KH2) by a yet-unknown enzyme3,4. VKOR is the target of the popular vitamin K antagonist (VKA) drug war-
farin, which is widely used to treat thrombosis5. Warfarin inhibits the activity of VKOR, thereby preventing the 
conversion of KO to KH2. KH2 is a necessary cofactor for GGCX which is responsible for the carboxylation of 
specific glutamic acid residues of vitamin K-dependent (VKD) proteins to γ-carboxyglutamic acid6. This carbox-
ylation of VKD proteins is an important post-translational modification required for the biological functioning of 
proteins involved in blood coagulation, bone mineralisation, and calcium homeostasis7. When functional defects 
in the vitamin K-cycle enzymes occur, the VKD proteins are only partially carboxylated, or are not carboxylated 
at all; these changes to VKD protein’s carboxylation severely affect its physiological functioning8.
VKOR uses two cysteines, the CXXC redox motif, as the active site for KO reduction9. The active site CXXC is 
conserved in all VKOR homologues in mammals, plants, and bacteria (except in fungi and yeast)10. Both cysteines 
in the CXXC active site motif are essential for the reduction of KO; mutating either one of these two cysteines 
reduces activity in all VKOR homologues9,11,12. Two additional cysteines, the loop cysteines, are present in the 
loop region between the first and second transmembrane domains (TMDs); these loop cysteines are also con-
served in the VKOR homologues10. An active site regeneration mechanism has been proposed for the bacterial 
homologue based on structure-function studies. In the proposed mechanism, the loop cysteines transfer electrons 
between the CXXC motif and a thioredoxin-like domain13–16. A similar active site regeneration mechanism has 
been proposed for mammalian VKOR17,18. However, mutating both of the loop cysteines in VKOR does not affect 
its enzymatic activity suggesting that these two loop cysteines are not required for active-site regeneration11,19,20.
In addition to the disputed role of the loop cysteines, there are two different proposed models of VKOR’s 
membrane topology; one model of VKOR as a 3-TM protein20,21 and one as a 4-TM protein18. The 4-TM model is 
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compatible with the well-known bacterial VKOR homologue; this model proposes that both the amino terminus 
(N-terminus) and the carboxyl terminus (C-terminus) are located in the cytosol and that both the loop and the 
active site cysteines face the ER lumen. The 3-TM model proposes that the N-terminus and the active site face 
the ER lumen, and that the loop cysteines and the C-terminus are located in the cytosol. One of the major differ-
ences between the 3- and 4-TM models of VKOR is the orientation of the first TMD. In the 4-TM model, the first 
TMD has the orientation of Nin/Cout which contradicts the “positive inside rule”22, a major factor that controls the 
orientation of a given TMD. In fact, one can alter the topology of a number of membrane proteins by changing 
their charged residue distributions flanking the TMD23,24. Previous results from our lab support the 3-TM topol-
ogy model of VKOR and demonstrate that the loop cysteines are unnecessary for active site regeneration20,21. 
Furthermore, computational simulations suggest that the 3-TM model of human VKOR is more stable than the 
4-TM model of human VKOR25.
Searches for genes homologous to VKOR identified a paralogous protein, VKORL, which shares nearly 50% 
protein sequence identity with VKOR and can reduce KO as efficiently as VKOR to support vitamin K-dependent 
carboxylation in vitro26–28. VKORL is reported to have a 30-fold higher resistance to VKAs than VKOR and to 
protect the extrahepatic tissues against the action of VKAs27. Therefore, it has been proposed that VKORL rescues 
VKOR activity in extrahepatic tissues during anticoagulation therapy. Although VKORL supports the reduction 
of KO in vitro, it does not appear to rescue VKOR activity, as it failed to rescue the VKOR-specific production of 
functional VKD clotting factors in VKOR knockout mice and VKOR knockout HEK293 cells19,29. Hammed et al., 
who measured the mRNA levels of VKOR and VKORL in various tissues of wild-type mice and VKOR knockout 
mice using qRT-PCR, report that the expression level of VKORL is unchanged in all tissues tested, indicating 
that VKOR and VKORL are regulated independently27. Furthermore, VKOR expression was found to be 10-fold 
higher than that of VKORL in liver tissue where the coagulation factors are produced; greater VKORL expression 
levels are observed in extrahepatic tissues where it could function to rescue VKA therapy.
VKOR has been extensively investigated, but structure-function studies of VKORL are inadequate. In this 
study, we established the structure-function differences between VKOR and VKORL using a VKOR and VKORL 
double gene knockout (DGKO) cell-based assay19. We used site-directed mutagenesis to introduce mutations at 
the critical residues in VKOR and VKORL, and observed the effects of these mutations on enzymatic activity and 
warfarin resistance. Additionally, differences in the disulfide-linked oligomerization between VKOR and VKORL 
were explored.
Results
VKOR and VKORL have different membrane topologies. Although it is accepted that VKORL is a 
4-TM protein, the membrane topology of VKOR is still under debate3. Both 3-TM and 4-TM topological models 
for VKOR have been proposed. In the 4-TM model, residues 75–97 function as the second TMD (TMD2), while 
in the 3-TM model, this region is defined as the cytoplasmic loop segment. This segment, if it stood alone, could 
be integrated into the ER membrane; however, it appears that in the full-length VKOR, this segment’s membrane 
integration is suppressed by the surrounding sequence21. Additionally, the membrane protein topology prediction 
program TMHMM predicts that the probability of the sequence 75–97 functions as a TMD in the full-length 
VKOR is small (<0.2) (Fig. 1A). We have previously shown that VKOR can be altered to a functional 4-TM 
molecule, the VKOR charge mutant (VKOR-CM), by mutating the charged residues flanking VKOR’s TMD120. 
In the 4-TM VKOR-CM, TMD2 (residues 75–97) has the lowest potential of being a transmembrane helix, and 
it could, therefore, be easily disturbed for membrane integration. It has been shown that introducing a proline 
residue into a TM helix can destabilize the membrane protein and affect its function30. Therefore, we hypothe-
sized that introducing a proline in the middle of the potential TMD2 (residues 75–97) would disrupt the protein 
function of only the VKOR charge mutant (VKOR-CM) (Fig. 1C), not of the wild-type VKOR (Fig. 1B). To test 
this hypothesis, we introduced a I86P mutation into both the wild-type VKOR and the VKOR-CM mutant, and 
determined the enzymatic activity of each mutant using our cell-based assay. The results show that the I86P muta-
tion has only a minor effect on the activity of VKOR, but it has a dramatic effect on the activity of the VKOR-CM 
mutant, decreasing its activity to ~10% (Fig. 1D). This result suggests that the potential TMD2 (residues 75–97) 
does function as an authentic TMD in the VKOR-CM mutant (4-TM model) but not in the wild-type enzyme, 
supporting the 3-TM model of VKOR.
As a comparison, we tested a similar mutation in VKORL by introducing a proline residue at I93 (the same 
location as I86, per the sequence alignment). Our results shown that introducing the proline residue did not 
affect the activity of VKORL (Fig. 1E), perhaps because residues 88–107 function in VKORL as a strong TMD, as 
predicted by the TMHMM program (probability close to 1.0). However, this mutation significantly increased its 
warfarin resistance (Fig. 1E). Nevertheless, the warfarin resistance of the I86P VKOR mutant is similar to that of 
the wild-type enzyme. These results, taken together, suggest that the potential TMD (residue 75–97) segment in 
VKOR does not function as an authentic TM helix and that VKOR, unlike VKORL, is a 3-TM molecule.
The P86S mutation in VKORL increased warfarin resistance by 20-fold. The sequence alignment 
between human VKORL and VKOR from different species shows that VKORL has a proline residue at position 
86, while in VKOR, this position has a conserved serine (S79) (Fig. 2A). Residue P86 is located at the membrane 
interface of the N-terminus of TMD2 in VKORL, in a similar location for residue S79 in the 4-TM model of 
VKOR. While in the 3-TM VKOR model, residue S79 is located in the cytoplasm. Proline residues at the mem-
brane interface of the TM helices often play an important role in correctly orienting essential residues for protein 
function by facilitating the formation of helix kinks and/or swivel angles31,32. We thought that the proline residue 
of P86 in VKORL might contribute to its function. If this is the case, the conserved residue S79 should have a 
similar function for the 4-TM model VKOR but not the 3-TM model VKOR. To test this hypothesis, we mutated 
P86 to serine in VKORL and S79 to proline in VKOR, and then determined the mutants’ activity and warfarin 
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resistance using our cell-based assay. Our results shown that the P86S VKORL mutant had slightly decreased activ-
ity, but significantly increased warfarin resistance (~20-fold increase over the wild-type enzyme; Fig. 2B and C). 
The enzyme activity and warfarin resistance of the S79P VKOR mutant, however, was comparable to that of the 
wild-type enzyme (Fig. 2D and E). Together, these results support the notion that P86 in VKORL is located in the 
ER lumenal interface of TMD2 on the same side as the active site; S79 in VKOR is not located at the membrane 
interface. Thus, these results support the 3-TM model of VKOR and the 4-TM model of VKORL.
Effect of sequences between the two conserved loop cysteines on the enzymatic activity of 
VKOR and VKORL. The different membrane topologies of VKOR and VKORL place the two conserved 
loop cysteines on different sides the ER membrane (Fig. 3A). We have shown that the conserved loop cysteines 
of VKOR (C43 and C51) are located in the cytoplasm, on the opposite side of the ER membrane from the active 
site cysteines; mutating both cysteines of VKOR does not significantly affect the enzyme activity20,26. However, 
the conserved loop cysteines of VKORL (C50 and C58) are located in the ER lumen, on the same side as the 
active site cysteines. VKORL’s loop cysteines are essential for its activity and are involved in active site regener-
ation26. To further examine the role of the loop region between the two conserved loop cysteines in both pro-
teins, we replaced the loop sequences of VKOR and VKORL with a HA tag sequence (YPYDVPDYA; Fig. 3A) 
and tested the activity of the resultant mutant proteins using our cell-based assay. We reasoned that if the con-
served loop cysteines are involved in transferring electrons to the enzyme’s active site, replacing the sequences 
between the two cysteines would affect the protein’s enzymatic activity. Our results indicate that the activity of the 
VKORL-HA-LOOP mutant is reduced to ~50% (Fig. 3B). Conversely, replacing the loop region in the VKOR with 
the HA tag sequence (VKOR-HA-LOOP) slightly increased the activity of the mutant protein (Fig. 3C). These 
Figure 1. Effect of helix-breaking proline residue on the proposed membrane topologies of VKOR and 
VKORL. (A) TMHMM prediction of VKOR membrane topology. The top line shows the predicted TMDs, and 
the striped lines indicate the probability of the regions’ functioning as the TMD. (B,C) Schematic representation 
of the membrane topology of VKOR and the VKOR charge mutant (VKOR-CM). The location of I86 is 
indicated. (D,E) Cell-based activity assay of VKOR, VKORL and their mutants. Wild-type VKOR, VKOR-
I86P, VKOR-CM and VKOR-CM-I86P mutants (D) were transiently expressed in HEK293-DGKO reporter 
cells, and the media was supplemented with 2.5 μM KO; 48 hours post-transfection, carboxylated reporter 
protein FIXgla-PC levels were measured by ELISA. Data is presented as mean ± SD of three independent 
experiments (n = 3), ***p < 0.001 (unpaired t-test) compared VKOR with VKOR-I86P and VKOR-CM with 
VKOR-CM-I86P. VKOR, VKOR-I86P, VKORL, and VKORL-I93P mutants (E) were transiently expressed 
in HEK293-DGKO reporter cells, and the cells were grown in media supplemented with 2.5 μM KO in the 
absence (black bars, KO) or presence (grey bars, KO + WF) of 2 μM warfarin 4 hours post-transfection; 48 hours 
later carboxylated FIXgla-PC concentration in the cell culture supernatant was measured by ELISA. Data is 
presented as mean ± SD of three independent experiments (n = 3), ***p < 0.001 (two-way ANOVA), compared 
to the respective VKOR or VKORL variant with KO and KO + warfarin (WF).
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results suggest that mutating the loop region of VKORL affects its enzyme activity; supporting the idea that the 
conserved loop cysteines of VKORL are involved in its active site regeneration.
VKOR, but not VKORL, has a characteristic ER retention signal. The function and structure 
of VKOR, an ER membrane protein that reduces KO to vitamin K in the vitamin K cycle, is well understood. 
However, the function of VKORL and its localisation within the cell organelles has not been defined. For exam-
ple, VKORL has been reported as being localised both within and outside the ER33,34. According to a search of 
the Eukaryotic Linear Motif (ELM) database for VKOR (ELM motif ID: TRG_ER_diLys_1), VKOR has a typical 
ER retention signal, KAKRH at the C-terminus of the protein. However, there is no characteristic ER retention 
signal identified for VKORL in the database. To determine the effect of VKOR’s ER retention signal to the pro-
tein’s function and subcellular localisation, we engineered an HPC4 tag (EDQVDPRLIDGK) at the C-terminus 
Figure 2. Effect of membrane interface proline residue on the activity and warfarin resistance of VKOR and 
VKORL. (A) Sequence alignment of hamster VKOR, rat VKOR, bovine VKOR, human VKOR and human 
VKORL. VKOR-S79 and VKORL-P86 residues are represented in boxes. Predicted TM and cytoplasmic 
regions of VKORL are indicated with graphics. (B) Cell-based activity assay of VKORL and its P86S mutant. 
HEK293-DGKO reporter cells were transiently transfected with VKORL and its P86S mutant and cultured with 
2.5 μM KO in the absence (black bars, KO) or presence (grey bars, KO + WF) of 2 μM warfarin 4 hours post-
transfection; 48 hours later, the media was collected, and the carboxylation of the FIXgla-PC reporter protein 
was measured by ELISA to evaluate the enzymatic activity. Data presented as mean ± SD of three independent 
experiments (n = 3), ***p = 0.001 (two-way ANOVA), compared with VKORL variant with KO and KO + WF. 
(C) Warfarin titration of VKORL and its P86S mutant. VKORL and its P86S mutant were transiently expressed 
in HEK293-DGKO cells and supplemented with 2.5 μM KO and varying levels of warfarin 4 hours post-
transfection. The carboxylated FIXgla-PC concentration in the cell culture media was determined using ELISA 
after 48 hours. (D) Cell-based activity assay of VKOR and its S79P mutant as described in (B), HEK293-DGKO 
reporter cells were transiently expressed with VKOR and the S79P mutant, and media was supplemented with 
2.5 μM KO in the absence (black bars, KO) or presence (grey bars, KO + WF) of 2 μM warfarin 4 hours post-
transfection; enzymatic activity was measured 48 hours post-transfection. Data presented as mean ± SD of three 
independent experiments (n = 3), ***p < 0.001 (two-way ANOVA), compared with VKOR variant with KO 
and KO + WF. (E) Warfarin titration of VKOR and its S79P mutant. VKOR and its S79 mutant were transiently 
expressed in the HEK293-DGKO reporter cells and the cells were cultured with 2.5 μM KO and increasing levels 
of warfarin; 48 hours later, enzymatic activity was measured as described above.
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of VKOR right after the ER retention signal, both with and without an additional KAKRH sequence. We then 
examined the enzymatic activity and the subcellular localisation of these constructs using our cell-based activity 
assay and immunofluorescence confocal imaging, respectively. For immunofluorescence confocal imaging, we 
co-expressed HPC4 tagged VKOR fusions with the ER marker protein mCherry-ER-3 in COS-7 cells. Our results 
showed that, while the HPC4 tagged protein with an additional KAKRH sequence is clearly localised to the ER 
membrane. Under the same conditions, the HPC4 tagged protein without the additional ER retention sequence 
shows a significantly lower fluorescence signal (indicating less intact protein expression) and faint fluorescence 
signal was observed in the non-ER organelles (Fig. 4A), suggesting the mislocalisation and probable misfolding 
of the HPC4 tagged protein without the additional ER retention sequence. Results from the cell-based activity 
assay show that introducing an HPC4 tag directly at the C-terminus of VKOR significantly decreases its activity 
(to ~20%). However, the HPC4 tagged protein with an additional KAKRH sequence is fully active (Fig. 4B) which 
is consistent with the immunofluorescence confocal results. These results together suggest that the ER retention 
signal is essential for the proper targeting and localisation of VKOR.
Similarly, we tested whether adding an HPC4 tag at the C-terminus of VKORL affected its activity and 
subcellular localisation. We also tested the influence of the ER retention sequence KAKRH as well as the last 
eight amino acids (RQLQPKQD) of VKORL on the HPC4-tagged VKORL (VKORL-HPC4-KAKRH and 
VKORL-HPC4-Repeat). Our results showed that VKORL-HPC4 and VKORL-HPC4-Repeat have a similar 
ER membrane localisation with distinct non-ER distributions (Fig. 4C). The addition of VKOR’s ER retention 
sequence KAKRH after the HPC4 tag significantly increased the ER localisation of VKORL. Compared with 
VKOR, significant non-ER distribution was observed for VKORL suggesting a possible non-ER localisation of 
the native protein. Functional study of these VKORL-HPC4 fusions shows that adding these HPC4 tag sequences 
does not affect the activity of VKORL (Fig. 4D), which is different from VKOR (Fig. 4B). This suggests that the 
ER retention signal, which is indispensable to VKOR’s activity, is not essential to the functioning of VKORL. 
Therefore, VKOR and VKORL could have different locations within the cell.
Figure 3. Exchanging the loop region between two conserved cysteines for an HA tag reduced the activity 
of VKORL. (A) Schematic illustration of VKOR and VKORL with their loop regions exchanged for HA 
tags (YPYDVPDYA). (B) Cell-based activity assay of VKORL and the VKORL-HA-LOOP mutant. VKORL 
and VKORL-HA-LOOP were transiently expressed in HEK293-DGKO reporter cells, and the media was 
supplemented with 2.5 μM KO. Forty-eight hours post-transfection, protein activity was determined by 
measuring the carboxylation of the reporter protein FIXgla-PC using ELISA. Data is presented as mean ± SD 
of three independent experiments (n = 3), ***p < 0.001 (unpaired t-test) compared VKORL with VKORL-
HA-LOOP (C), VKOR and VKOR-HA-LOOP were expressed in HEK293-DGKO cells, and the media was 
supplemented with 2.5 μM KO; 48 hours post-transfection, protein activity was measured by ELISA. Data is 
presented as mean ± SD of three independent experiments (n = 3), **p = 0.002 (unpaired t-test) compared 
VKOR with VKOR-HA-LOOP.
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VKORL and VKOR form disulfide-linked homo-oligomers. It has been reported that under 
non-reducing conditions, VKOR exists as a multimeric structure35 or forms a hetero-dimer with VKORL36. The 
expression levels of VKOR and VKORL are tissue-specific; VKOR is mainly expressed in the liver, and VKORL 
is mainly detected in brain tissues27. To examine the possible oligomerization of VKOR and VKORL, we fused 
a FLAG tag at the C-terminus of both enzymes to facilitate their determination by western blot. First, we tested 
the effect of FLAG tag on the activity of VKOR and VKORL using our cell-based activity assay. Results in Fig. 5A 
show that adding a FLAG tag at the C-terminus of both enzymes does not have significant effect on their enzy-
matic activity. Next, we determined the subcellular location of the FLAG-tagged VKOR and VKORL. Our results 
Figure 4. ER retention signal KAKRH is essential for VKOR activity and localisation. (A) Immunofluorescence 
confocal imaging of HPC4 tagged VKOR. VKOR-HPC4 or VKOR-HPC4-KAKRH was co-expressed with 
the ER marker mCherry-ER-3 in Cos-7 cells. Forty-eight hours posttransfection, transfected cells were fixed 
with paraformaldehyde, permeabilised with Triton X-100, and immune-stained with mouse anti-HPC4 as 
the primary antibody and Alexa Fluor 488 conjugated donkey anti-mouse IgG as the secondary antibody. 
Cell nucleus was stained with Hoechst 33342. Due to the significant low signal of the green channel for 
VKOR-HPC4 fusion, the Gain of the green channel was increased from 600 (for VKOR-HPC4-KAKRH 
construct) to 760. (B) Effect of the ER retention signal on VKOR activity. VKOR, VKOR-HPC4 and VKOR-
HPC4-KAKRH were transiently expressed in HEK293-DGKO cells and cultured with 2.5 μM KO; 48 hours 
post-transfection, carboxylation of the secreted FIXgla-PC was measured by ELISA. Data is presented as 
mean ± SD of three independent experiments (n = 3), ***p = 0.001 (unpaired t-test) compared with VKOR. (C) 
Immunofluorescence confocal imaging of HPC4 tagged VKORL. VKORL-HPC4, VKORL-HPC4-Repeat, or 
VKORL-HPC4-KAKRH was co-expressed with the ER marker mCherry-ER-3 in Cos-7 cells. Forty-eight hours 
post-transfection, transfected cells were treated as described in (B). (D) Effect of the ER retention signal on 
VKORL activity. VKORL, VKORL-HPC4, VKORL-HPC4-KAKRH and VKORL-HPC4 repeat DNA (VKORL’s 
last eight amino acids RQLQPKQD) were transfected into the HEK293-DGKO cells and cultured in growth 
medium containing 2.5 μM KO for 48 hours; the carboxylated FIXgla-PC concentration in the cell culture 
supernatant was then measured by ELISA. Data is presented as mean ± SD of three independent experiments 
(n = 3), *p = 0.033 (unpaired t-test) compared with VKORL.
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show that VKOR has a clear ER membrane localisation, while VKORL shows distinct non-ER localisation 
(Fig. 5B), which is consistent with the results of the HPC4 tagged protein (Fig. 4).
Next, we determined the oligomerization of VKOR and VKORL in different cell types. We expressed both 
proteins in neural cell lines SK-N-MC and Neuro-2a, and in a human kidney cell line, HEK-293. The western blot 
result under non-reducing conditions (Fig. 5C) indicated that VKORL forms two disulfide-linked oligomers at 
~37 kDa and ~52 kDa. There was no difference in oligomerization between the three cell lines tested. We observed 
a similar disulfide linkage with VKOR in all three-cell lines (Supplementary Fig. 1). Both of these oligomers dis-
appeared under reducing conditions (in the presence of DTT) (Fig. 5C), suggesting that they are disulfide-linked 
oligomers.
Figure 5. Analysis of disulfide linkage in VKORL and VKOR. (A) Cell-based activity assay of the VKOR, 
VKOR-FLAG, VKORL, and VKORL-FLAG. All constructs were transiently expressed in HEK-293 DGKO 
cells and the media was supplemented with 2.5 μM KO; 48 hours after transfection, protein activity was 
determined by quantifying the carboxylation of the reporter protein FIXgla-PC using ELISA. Data is presented 
as mean ± SD of three independent experiments (n = 3), unpaired t-test was performed to compare VKOR with 
VKOR-FLAG and VKORL with VKORL-FLAG. The results from the unpaired t-test are not significant. (B), 
Immunofluorescence confocal imaging of FLAG tagged VKOR and VKORL. VKOR-FLAG or VKORL-FLAG 
was co-expressed with the ER marker, mCherry-ER-3, in Cos-7 cells. Forty-eight hours post-transfection, 
transfected cells were fixed with paraformaldehyde, permeabilised with Triton X-100, and immune-stained 
with mouse anti-FLAG and Alexa Fluor 488 conjugated donkey anti-mouse IgG. Cell nucleus was stained with 
Hoechst 33342. (C) Disulfide-linked oligomerization of VKORL in different cell lines. HEK293, SK-N-MC and 
Neuro-2a cells were transiently transfected with VKORL-FLAG; 48 hours post-transfection, cells were lysed and 
subjected to Western blot analysis using anti-FLAG antibody under both reducing (+DTT) and non-reducing 
(-DTT) conditions. (D) Western blot analysis of co-expression of VKOR and VKORL. HEK293-DGKO cells 
were transfected with different constructs as indicated; 48 hours after transfection, cells were lysed under 
non-reducing conditions, and the input was detected using anti-FLAG antibody. (E) Western blot analysis 
of artificial oligomerization of VKOR and VKORL during the cell lysis. HEK-293 cells were transfected with 
VKOR-FLAG and VKORL-FLAG and 48 hours post-transfection cell were lysed in the presence of 50 mM NEM 
and analysed using Western blot under non-reducing (-DTT) conditions. Blots were cropped to improve the 
clarity and conciseness of the result. The molecular weight marker is indicated to the left of the picture. Mock is 
the sample from untransfected cells. Full image blots are presented in Supplementary Figure 2A,B and C.
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As VKOR has been co-immunoprecipitated with itself and with its paralogous protein VKORL36, we asked 
whether these oligomers might be due to the interaction between VKOR and VKORL. Therefore, we used 
HEK293-DGKO cells (endogenous genes of both VKOR and VKORL were knocked out)19 to express VKOR and 
VKORL individually and together, then probed the oligomerization of each of the proteins using Western blot 
analysis under non-reducing conditions (Fig. 5D). The results indicated that co-expressing VKORL with VKOR 
showed similar patterns to VKOR or VKORL when expressed alone (Fig. 5D). This suggests that the oligomers of 
VKOR and VKORL are homogeneous. To determine whether the disulfide-linked oligomerization of VKOR and 
VKORL exists within the cells in native conditions, we blocked the free cysteines while lysed the cells by adding 
50 mM N-Ethylmaleimide (NEM) to the lysis buffer and performed Western blot under non-reducing conditions. 
Our results showed that the disulfide-linked oligomers of VKOR and VKORL were significantly reduced in the 
NEM treated samples but, were not abolished (Fig. 5E). Additionally, two forms of disulfide-linked oligomers 
were observed in the NEM blocked VKORL sample with dramatically reduced intensity; while only one oligomer 
was observed in the NEM blocked VKOR sample with substantial intensity. These results suggest that cysteines in 
these two enzymes play different roles, which is consistent with previous studies20,26.
The cysteine residues involved in the disulfide-linked oligomerization in VKOR and VKORL are 
different. To investigate the cysteine residues involved in VKORL’s oligomer formation, we mutated each of 
the individual cysteines (C23S, C50S, C58S, C139S, and C142S) (Fig. 6A and C) and two cysteine pairs: C50–
139S and C50–142S. We chose double cysteine mutation combinations because, as we have previously shown, 
C58 forms an intramolecular disulfide with C139 during KO reduction26. We expressed these mutant proteins 
in HEK293-DGKO cells and probed oligomerization using western blot analysis. We found that there was no 
change in VKORL oligomerization after the mutation of any individual cysteine or the C50–139S double cysteine 
(Fig. 6A). However, mutating the C50 and C142 together to serine abolished the formation of oligomerization, 
Figure 6. Identification of cysteine residues involved in disulfide linkage in VKOR and VKORL. (A) Western 
blot analysis of oligomerization of VKORL and its cysteine mutants. HEK293-DGKO cells were transfected 
with VKORL and its cysteine mutants as indicated. Cells were harvested 48 hours post-transfection, and the 
cell lysates were subjected to Western blot under non-reducing conditions using anti-FLAG antibody. (B) 
Western blot analysis of oligomerization of VKOR and its cysteine mutants. Western blot was performed under 
non-reducing conditions using the lysate prepared from HEK293-DGKO cells transfected with VKOR and 
its cysteine mutants as indicated; the input was detected using anti-FLAG antibody. (C) Proposed membrane 
topology cartoon of VKORL and VKOR showing the location of the conserved cysteines. All cysteine residues 
were coloured red, and the conserved cysteines between VKOR and VKORL are boxed. The figure represents 
the grouping of different parts from two blots (A and B), and a black dividing line indicates the spliced image. 
The molecular weight marker is indicated to the left of the picture. Mock is untransfected cells. Blots were 
cropped and joined to improve the clarity and conciseness of the result. Full-length blots are presented in 
Supplementary Figure 3A and B.
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indicating that these two cysteines together are responsible for VKORL’s oligomer formation (Fig. 6A). This result 
is consistent with the location of C50 and C142 in the oxidative milieu of the ER lumen.
Similarly, we analysed the cysteine residues involved in the disulfide linkages of VKOR by mutating seven 
individual cysteines (C16A, C43A, C51A, C85A, C96A, C132A, and C135) (Fig. 6B and C) and two cysteine pairs 
(C43–132A and C43–135A). We expressed these mutant proteins in HEK293-DGKO cells and analysed their oli-
gomerizations using western blot analysis. None of the tested cysteine mutations prevented the formation of oli-
gomers (Fig. 6B). It has been shown that C51 and C132 form an intramolecular disulfide during KO reduction37. 
Therefore, as we did in VKORL, we tested the oligomerization of the VKOR-C51-132A and VKOR-C51-135A 
mutants. We observed no difference in the disulfide linkage from that of wild-type VKOR (Supplementary Fig. 3). 
Unlike VKORL, VKOR’s single and double cysteine mutants still form oligomers, indicating that the disulfide 
linkage patterns by which the VKOR and VKORL form oligomers are different.
Discussion
VKOR is one of the key enzymes in the vitamin K cycle, which is essential for posttranslational modification of 
VKD proteins. Although VKORL has a high sequence identity with VKOR, VKORL’s exact physiological function 
is still unknown. The biochemical characterization of VKORL is proposed to have unrelated physiological func-
tions including acting as an intracellular antioxidant38 and rescuing VKOR activity in extrahepatic tissues during 
anticoagulation therapy27. Clarifying the structural and functional differences between VKOR and VKORL could 
provide insights into their physiological functions.
The structure-function characterization of VKOR has yielded disputed topological structures and mecha-
nisms for active site regeneration. A 4-TM topology model has been proposed for VKOR, based on the crystal 
structure of its bacterial homologue18. However, biochemical and cell-based studies of human VKOR suggest 
a 3-TM structure20,21. The results presented in this study (Fig. 1D and E) are in line with our previous findings 
indicating that VKOR is a 3-TM protein, unlike VKORL, which appears to be a 4-TM protein. If VKOR were a 
4-TM protein, the sequence from residue I75 to L97 would function as the second TMD, and that introducing a 
TM helix-breaking proline residue between I75 and L97 would likely affect protein function. Results from Fig. 1 
show that the I86P mutant has similar activity and warfarin-binding affinity to the wild-type enzyme. However, 
a similar proline insertion in a VKOR charge mutant (a VKOR molecule with its topology altered to 4-TM20) 
results in a significant decrease in enzymatic activity (to ~10%). In contrast, substituting a proline for VKORL I93 
(a similar location to VKOR I86) significantly increased VKORL’s warfarin resistance with only a minor effect on 
the enzymatic activity; the activity remained stable, which could be because the region where the I93P mutation 
was introduced was predicted to be a very strong TMD by TMHMM. Introducing a single proline mutation in 
this location may not be sufficient to break the helix or to have a significant effect on the enzyme activity. Another 
clear structural difference between the two proteins is the location of certain crucial residues, which has an effect 
on the protein’s function. VKORL’s proline residue P86 is located near the lumenal ER membrane surface of 
TMD2, where the reduction of KO occurs; VKOR S79 (the analogous residue to VKORL P86) and the sequences 
that follow it (which comprise the potential TMD) are located in the cytoplasm of the 3-TM model, on the 
opposite side of the enzyme’s active site. Mutating VKORL residue P86 increased its warfarin resistance by ~20 
fold (Fig. 2C); however, mutating VKOR S79 to proline had no effect on VKOR’s activity or warfarin resistance. 
Together, these results support our proposition that VKOR and VKORL are structurally different.
VKOR appears to carry a characteristic ER retention signal, KAKRH, which must be at the end of the pro-
tein for proper functioning. Covering this ER retention signal by fusing an HPC4 tag sequence at the end of the 
KAKRH sequence (meaning that KAKRH was no longer identifiable as being in the correct location) dramatically 
decreased VKOR activity (Fig. 4B). However, the decreased VKOR activity was restored by adding another ER 
retention sequence, KAKRH, after the HPC4 tag sequence. In contrast, VKORL has no predicted ER retention 
signal; fusing an HPC4 tag sequence at VKORL’s C-terminal, adding an additional KAKRH sequence or part of 
the C-terminal sequence of VKORL after the HPC4 tag sequence does not affect VKORL’s activity. These differ-
ences suggest a different localisations of these two proteins in the physiological conditions, which agree with the 
previously reported non-ER localisation of VKORL33,34, implying that VKORL may have a different physiological 
function than VKOR.
Our previous findings indicated that VKORL’s active site is regenerated by transferring electrons from the loop 
cysteines26. This concept is further supported by the results of the current study, which show a 50% reduction in 
VKORL’s enzymatic activity when the amino acid residues between the loop cysteines are exchanged with the 
HA tag sequence (Fig. 3B). A similar exchange in VKOR has no effect on the protein’s enzymatic activity, which 
suggests that the loop region is not essential for VKOR activity; again, this agrees with our previous findings26 and 
indicates that the structure of VKOR differs from that of VKORL.
Our results showed that VKOR could form disulfide-linked oligomers (Fig. 5), which is consistent with the 
proposed multimeric structure of VKOR35. Mutating the cysteine residues to characterise the disulfide linkage 
revealed that, in VKOR, by mutating each individual cysteine or combinations of double cysteine mutations 
(C43–132 A, C43–135 A, C51–135 or C51–135), were unable to abolish the disulfide-linked oligomer forma-
tion (Fig. 6B). The same test indicated that in VKORL, the double cysteine (C50 and C142) mutation prevents 
the disulfide-linked oligomerization suggesting that these two cysteines are responsible for oligomer formation 
(Fig. 6A). These results indicate that both VKOR and VKORL form similar disulfide-linked oligomers, but that 
the cysteine residues involved in disulfide linkage are different in the two proteins. Although, it is reasonable that 
the two cysteines responsible for the disulfide-linked oligomerization in VKORL are located in the ER lumen, 
an oxidizing environment, the logic of the disulfide-linked oligomerization of VKOR is not clear, as none of its 
cysteines are located in the ER lumen. Whether this disulfide formation has some physiological function in higher 
species need to be further explored.
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Overall, our findings suggest that VKOR and VKORL are structurally and functionally different; suggesting 
that VKORL may have other physiological functions besides reducing KO to support vitamin K-dependent car-
boxylation. Further studies are needed to identify the physiological partners/reductants of VKORL to determine 
its exact cellular function.
Methods
Chemicals and Materials. Polyvinylidene difluoride (PVDF) membrane and ECL chemiluminescence rea-
gent were purchased from GE Healthcare Bio-Sciences (Pittsburgh, PA,USA). Mammalian expression vectors 
phCMV1 and Xfect transfection reagent were bought from Takara Bio USA, Inc. (Mountain View, CA, USA). The 
Quick-change site-directed mutagenesis kit was from Stratagene (San Diego, California, USA). Q-5 DNA poly-
merase and T4 DNA ligase were obtained from New England Bio Labs (Ispwich, MA). HEK293, SK-N-MC and 
Neuro-2a cells were from ATCC (Manassas, VA, USA). Restriction enzymes and pre-stained protein ladders were 
obtained from Thermo Fisher Scientific (Waltham, MA, USA). Cell culture media, PBS, pBudCE 4.1 mammalian 
dual expression vector, 4X LDS buffer and NuPAGE™ Novex™ 4–12% Bis-Tris Protein Gels were purchased 
from Life Technologies (Carlsbad, CA, USA). Fetal bovine serum (FBS) and FLAG monoclonal antibody were 
from Sigma-Aldrich (St. Louis, MO, USA). Mouse anti-carboxylated FIXgla antibody was from Green Mountain 
Antibodies (Burlington, VT, USA). Goat anti-mouse IgG and horseradish peroxidase (HRP) conjugated sheep 
anti-human protein C IgG were from Affinity Biologicals, Inc. (Ancaster, ON, Canada). The 96-well plates for 
the ELISA, the Hygromycin A antibiotic, and the plastics for the cell culture were from Corning Inc. (New York, 
NY, USA). The cOmplete™ protease inhibitor cocktail tablets were purchased from Roche (Basel, Switzerland).
Cell culture and transfection. HEK-293, SK-N-MC and Neuro-2a cells were cultured in DMEM F-12 
media supplemented with 10% FBS and 1% Penicillin/Streptomycin. HEK293-DGKO reporter cells were cultured 
in DMEM F12 media with 10% FBS and 0.1 mg/ml Hygromycin A to maintain the stability of the reporter gene, 
FIXgla-PC. All transfections were performed using Xfect transfection reagent, according to the manufacturer’s 
protocol.
Expression vector construction and DNA manipulation. For mammalian cells expression, 
VKOR or VKORL gene was cloned into the phCMV1 vector with either a FLAG or a HPC4 tag fused at the 
C-terminus. For C-terminal FLAG tag construction of VKORL, two primers were used: a 5′ primer with a Kozak 
sequence flanked by the XhoI restriction site, and a 3′ primer with a flexible (GGSG)2 linker, flanked by the 
FLAG tag (DYKDDDDK) and the KpnI restriction site. For VKOR C-terminal FLAG tag fusion, an additional 
ER retention signal sequence (KAKRH) was added to the C-terminus of the FLAG tag. Similarly, a HPC4 tag 
(EDQVDPRLIDGK) was fused to the C-terminus of VKOR or VKORL using a 3′ primer with a flexible (GGSG)2 
linker and a HPC4 tag sequence flanked by XhoI restriction site. Additional sequences of the ER retention signal 
sequence or a short repeat sequence of the C-terminus of VKORL was added to the C-terminus of the HPC4 tag 
sequence as indicated in the text. To replace the loop sequence between the two conserved cysteines with HA tag 
(YPYDVPDYA) in the wild-type VKOR and VKORL, we used overlap PCR. For the in vivo cell-based activity 
assay, either VKOR or VKORL gene constructs was sub-cloned into the mammalian dual gene expression vector 
pBudCE 4.1, between HindIII (5′) and XbaI (3′). No affinity tags were added to the VKOR or VKORL constructs 
used for the in vivo cell-based activity assay. Unless otherwise specified all the affinity tags were added to the 
C-terminus, and no construct was tagged with two different affinity tags. All the VKOR and VKORL cysteine 
mutants (Fig. 6A and B) have FLAG tag at the C-terminus.
Site-directed mutagenesis was performed using the Quick-change mutagenesis kit according to the manufac-
turer’s instructions. All the primers and the DNA sequencing was carried out by Eton Bioscience (Durham, NC, 
USA).
Immunofluorescence confocal imaging. Subcellular localisation of HPC4 or FLAG tagged VKOR and 
VKORL were examined by immunofluorescence confocal imaging. HPC4 or FLAG tagged VKOR or VKORL 
was transiently co-expressed with the ER marker, mCherry-ER-3 (a gift from Dr. Michael Davidson, Addgene 
plasmid # 55041), in COS-7 cells on glass coverslips. Forty-eight hours post-transfection, cells were washed three 
times with PBS and fixed with 4% paraformaldehyde for 15 minutes. Fixed cells were permeabilized with 0.25% 
Triton X-100 for 10 min. Permeabilized cells were washed three times with PBS and blocked with 2% bovine 
serum albumin and 5% fetal bovine serum for one hour. Cells were then incubated with mouse anti-HPC4 or 
anti-FLAG monoclonal antibody in blocking buffer for one hour. After washing three times, cells were incubated 
with Alexa Fluor 488 conjugated donkey anti-mouse IgG for one hour. Cells were washed again for three times 
and the cell nuclei were stained with 2 µM Hoechst 33342 (Life Technologies, Carlsbad, CA) in PBS for 20 min-
utes. Coverslips were mounted onto glass slides with ProLong Gold antifade reagent (Thermo Fisher Scientific, 
Rockford, IL). Confocal microscopy was performed on a Zeiss LSM710 confocal laser scanning microscope (Carl 
Zeiss Microimaging, Thornwood, NY). Images were collected using a 40X/1.2NA C-Apochromat objective lens. 
Visualization of the Hoechst 33342 staining was achieved using a 405 nm diode laser for excitation with the 
detector set to collect emission at 406–485 nm. Visualization of the Alexa Fluor 488 staining was achieved using 
a 488 nm argon laser line for excitation with the detector set to collect emission at 505–544 nm. Visualization 
of mCherry was achieved using a 561 nm diode laser for excitation with the detector set to collect emission at 
565–701 nm.
Detection of FLAG-tagged proteins by immunoblotting. FLAG-tagged VKOR, VKORL or their var-
iants were transiently expressed in one of the following types of cells: HEK-293, HEK-293-DGKO, SK-N-MC or 
Neuro-2a. Forty-eight hours post-transfection, cells were harvested and lysed in a lysis buffer (150 mM NaCl, 
20 mM Tris/HCl (pH 7.4), 1% Triton X-100, 1X Roche cOmplete™ protease inhibitor cocktail). Samples were 
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boiled in 1X LDS buffer for 5 min. For some experiments, cells were lysed using the lysis buffer (150 mM NaCl, 
20 mM Tris/HCl (pH 7.4), 1% Triton X-100, 1X Roche cOmplete™ protease inhibitor cocktail) with 50 mM 
N-Ethylmaleimide (NEM) to prevent the artificial disulfide linkage. Proteins were separated by sodium dodecyl 
sulfate–polyacrylamide gel electrophoresis (SDA-PAGE) using NuPAGE™ Novex™ 4–12% Bis-Tris protein gels. 
After the SDS-PAGE separation, protein bands were transferred onto the PVDF membrane using the wet transfer 
method for 1 hour at 60 V. The blotted membrane was blocked for 1 hour in 5% non-fat milk in TBST (50 mM 
Tris-Cl, pH 7.5, 150 mM NaCl, 0.1% Tween) at room temperature, then incubated with anti-FLAG antibody 
(F3165, Sigma-Aldrich, 1:2000) for 1 hour in the TBST buffer. The membrane was washed (3 × 10 min) with 
TBST, then incubated with HRP-conjugated goat anti-mouse IgG antibody (GAM-APHRP, Affinity Biologicals, 
Inc. 1:4000) for an hour. This was followed by another 3 × 10 min wash. The protein signals were then detected 
using ECL PLUS reagent, and the bands were visualised using Amersham Hyperfilm ECL (28906836, GE 
Healthcare, USA)
Cell-based VKOR and VKORL activity assay. The activity of VKOR, VKORL, and their mutants was 
measured using our cell-based activity assay39. This assay was performed in HEK293-DGKO reporter cells, where 
genes for both VKOR and VKORL were knocked out to eliminate any interference with endogenous KO reduc-
tase activity. A chimeric VKD protein, FIXgla-PC (protein C with its Gla domain replaced by that of factor IX), 
was stably expressed in the DGKO cells as the reporter protein. The functionality of VKOR, VKORL and their 
variants was measured, similar constructs were transiently transfected in a pBudCE4.1 vector to HEK293-DGKO 
reporter cells in a 24-well plate using Xfect transfection reagent. Five hours after transfection, the transfection 
media was exchanged for fresh media with 2.5 μM KO added. The cell culture media was collected 48 hours 
post-transfection and subjected to sandwich ELISA to measure the levels of carboxylated FIXgla-PC reporter 
protein, as described previously39.
Warfarin titration assay. For the warfarin resistance study, the VKOR or VKORL genes were transiently 
expressed in HEK293-DGKO cells. Four hours later, 2.5 µM of KO with increasing concentrations of warfarin was 
added. The cell culture supernatant was collected 48 hours post-transfection, and carboxylation of the FIXgla-PC 
protein was measured by ELISA to determine its activity. The half-maximal inhibitory concentrations of (IC 50) 
values were measured using Graphpad Prism 7.0 software (GraphPad Software Inc., San Diego, CA, USA) to 
determine the warfarin resistance levels of the VKOR and VKORL mutants.
Statistical analyses. For each data group, results were expressed as the mean ± SD (standard deviation), 
and ‘n’ indicates the number of experimental replicates used for the analysis. Statistical analysis was carried out 
by comparing the VKOR or VKORL mutants with their corresponding control. Differences between the two 
groups were assessed using the unpaired t-test. A 2way ANOVA was used to determine the differences between 
more than two groups (Sidak’s multiple comparison test). The statistical significance criteria was set as P < 0.05. 
GraphPad Prism 7.0 Software was used to perform the statistical analysis (GraphPad Software Inc., San Diego, 
CA, USA).
Data Availability. The datasets generated and analysed during the current study are included in this pub-
lished article
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